Shattuck Labs to Host Investor Call and Webcast on New Data at EHA 2024 Congress

Shattuck Labs, Inc. (Nasdaq: STTK), a clinical-stage biotechnology firm innovating in the realm of bifunctional fusion proteins for cancer and autoimmune diseases, has announced an upcoming investor call. This call will provide an interim safety and efficacy update from the Phase 1B dose expansion clinical trial of their leading compound, SL-172154, when combined with azacitidine (AZA) in patients with high-risk myelodysplastic syndromes (HR-MDS) and TP53-mutated acute myeloid leukemia (TP53m AML). The detailed presentation will take place at the EHA 2024 Congress and will be led by Dr. Naval G. Daver from The University of Texas MD Anderson Cancer Center.

The conference call is scheduled for Friday, June 14, 2024, at 7:30 a.m. ET. Interested parties can access the live webcast through the Investor Relations page on Shattuck Labs' website. Advance registration is required for participation, and a replay option will be made available for those who cannot join the live event.

Dr. Naval G. Daver, the primary investigator for this trial, holds a distinguished position as the Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center. Dr. Daver completed his medical education at Grant Medical College and Sir J Group of Hospitals in Mumbai, followed by a residency and fellowship in hematology-oncology at Baylor College of Medicine. His research is focused on molecular and immune therapies in acute myeloid leukemia (AML) and myelofibrosis. Dr. Daver is the principal investigator for over 25 ongoing clinical trials aimed at developing tailored therapies targeting specific mutations or immune pathways in AML patients. His work includes evaluating novel combinations of targeted, immune, and cytotoxic agents and addressing mechanisms of resistance. He is particularly interested in developing monoclonal and bispecific antibodies, immune checkpoint inhibitors, CD47 antibodies, and vaccine-based approaches for AML, MDS, and myelofibrosis. Dr. Daver has authored more than 450 peer-reviewed manuscripts and serves on the editorial board of multiple hematology-specific journals. He is also a regular contributor to national and international conferences.

Shattuck Labs is at the forefront of developing bi-functional fusion proteins, a novel class of biologic medicine designed to treat cancer and autoimmune diseases. The company’s proprietary Agonist Redirected Checkpoint (ARC®) platform aims to concurrently inhibit checkpoint molecules while activating costimulatory molecules within a single therapeutic agent. Their leading program, SL-172154 (SIRPα-Fc-CD40L), is engineered to block the CD47 immune checkpoint while also activating the CD40 pathway, which is currently under evaluation in multiple Phase 1 trials. Shattuck Labs operates out of Austin, Texas, and Durham, North Carolina. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!